Oneness Biotech Co., LTD receives a China patent on antagonistic LAG-3 aptamers.

Published Date:2025-02-06

Statement
No	1	Date of announcement	2025/02/06	Time of announcement	18:27:31
Subject	Oneness Biotech Co., LTD receives a China patent on antagonistic LAG-3 aptamers.
To which item it meets	paragraph 53			Date of events	2025/02/06
Date of occurrence of the event: 2025/02/06 Company name: ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office Reciprocal shareholding ratios: NA Cause of occurrence: The Company has been informed by the patent agency that the antagonistic LAG-3 aptamer has been granted a China patent titled ”NUCLEIC ACID APTAMERS TARGETING LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND USES THEREOF” under patent number ZL2019800538655. Countermeasures: None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): This patent covers the aptamers that bind to and antagonize LAG-3 and uses thereof in modulating immune responses, enhancing T cell activity and /or inhibiting cancer growth.